Contract Pharma Manufacturing News

  1. WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production At Pilot-Scale 8/12/2025

    Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale.

  2. Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing Of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology 8/12/2025

    Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology.

  3. AbbVie Announces $195M Investment To Expand Active Pharmaceutical Ingredient Manufacturing In The U.S. 8/12/2025

    AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S.

  4. Intas & Accord Signs Agreement To Acquire Prothya Biosolutions 8/11/2025

    Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium.

  5. Quantum BioPharma Signs Agreement To Manufacture Oral Drug Formulation Of Its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) For Use In Its Upcoming Phase 2 Multiple Sclerosis Trial 8/11/2025

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS.

  6. Sartorius Stedim Biotech And Nanotein Technologies Partner To Advance Cell Therapy Manufacturing 8/11/2025

    Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. As part of the collaboration, Sartorius Stedim Biotech will invest up to 3 million US dollars in a minority shareholding in Nanotein Technologies to support the commercialization and joint development of solutions based on its NanoSpark platform.

  7. ProBio Launches GMP AAV Manufacturing Services At Hopewell Facility To Advance Gene Therapy Development And Manufacturing 8/11/2025

    ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art facility in Hopewell, New Jersey.

  8. Cosmo And Takeda Renew Strategic Manufacturing Agreement For Global Supply Of Oral Treatment For Ulcerative Colitis 8/8/2025

    Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda, to produce Mesalazine MMX 1200 mg (marketed as Lialda in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.

  9. Fujifilm And HORIBA Co-Developed Gene Delivery System To Enhance Productivity In Gene Therapy Manufacturing 8/7/2025

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) and HORIBA, Ltd. (President: Masayuki Adachi) today announced the co-development of a novel gene delivery system that significantly enhances productivity in the manufacture of gene therapy products.

  10. Excellos, Lonza, And Akadeum Life Sciences Unite To Advance Cell Therapy Manufacturing Through Enhanced Starting Material Quality 8/6/2025

    Excellos, Lonza, and Akadeum Life Sciences today announce a new project aimed at redefining standards for cell therapy manufacturing by elevating the role of starting material quality.